Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
8 evidence topics · 7 sources
Summary
In the NATIVE trial at week 24, in the full analysis population with missing data handled by multiple imputation, a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) occurred in 55% of participants receiving lanifibranor 1200 mg (significant) and 48% receiving 800 mg (not significant), compared with 33% receiving placebo; resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%. The company topline release reported the primary end point in the ITT population as 49% (1200 mg, P=0.004), 41% (800 mg, P=0.061), and 27% (placebo). The trial publication states that fibrosis is the primary predictor of complications and death in NASH and that regression of fibrosis is associated with decreased risk of liver-related events.
Evidence linking fibrosis stage to outcomes comes from pooled cohort studies and models. Across cohort studies of biopsy-proven NAFLD, stage 3 to 4 fibrosis carried higher all-cause (HR 3.32) and liver-related mortality (HR 10.40) than stage 0 to 2. The estimated time to progress by one stage was 13.3 years from F2 and 22.2 years from F3, and the time to regress by one stage was 12.5 years from F3 and 20.4 years from F2. A US model estimated that a hypothetical therapy halting fibrosis progression in MASLD would reduce cases of decompensated cirrhosis by 11-39%, hepatocellular carcinoma by 10-34%, and liver-related deaths by 8-31%. The AASLD resmetirom update states that stabilization of fibrosis may portend important long-term benefits. The EASL guideline states that agents receiving accelerated approval for MASH must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, and hepatocellular carcinoma).
NATIVE: histologic response at week 24, full analysis population with multiple imputation
Fibrosis regression as a predictor of reduced liver-related events (NATIVE discussion)
Mortality by fibrosis stage in biopsy-proven NAFLD (meta-analysis of 14 studies)
“Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05). Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stage 3 to 4 fibrosis had a higher all-cause (HR, 3.32) and liver-related mortality (HR, 10.40) compared with stage 0 to 2 fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Untreated progression and regression times per fibrosis stage (meta-analysis of 54 studies)
“Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled US outcomes of a therapy that halts fibrosis progression in MASLD with moderate-to-advanced fibrosis
“The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote